Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of TAK-559 Monotherapy in Type 2 Diabetes
NCT00763022Phase 3Completed
- Sponsor
- Takeda
- Start
- Nov 2003
- Primary completion
- Dec 2004
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of imiglitazar in type 2 diabetes mellitus (T2DM), sponsored by Takeda. Started Nov 2003; status: completed.
02
Drugs
imiglitazar
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00763022.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00763022.